CTRI/2014/01/004341已完成4 期
A PHASE III, RANDOMIZED, MULTICENTERIC, CONTROLLED STUDY TO EVALUATE THEIMMUNOGENICITY AND SAFETY OF BBILs TYPHOID Vi CAPSULARPOLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCEVACCINE IN HEALTHY SUBJECTS. - Typbar TCV
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 981
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.Provide voluntary written and signed informed consent from volunteer or if minor from parent/legal guardian.
- •2.Healthy subjects in two cohorts aged 6 to 24 months, and 2 - 45 years.
- •3.Are not participating in or plan to participate in another research during the next three months & be available throughout study period.
- •4.Family does not plan to move during the study period, and housed not further that 50 Km away from the study site
排除标准
- •1)Fever of any origin or infections more than 3 days within one month prior
- •to screening or on the day of screening
- •2)Any confirmed or suspected immunosuppressive condition.
- •3)Any treatment with immunosuppressive or immunostimulant therapy
- •4)Use of any marketed or investigational or herbal medicine or non-registered drug or vaccine for typhoid.
- •5)Life threatening or serious cardiac (NYHA grade 3&4), respiratory, gastrointestinal, hepatic, renal, endocrine and systemic disorders.
- •6)Have been vaccinated against typhoid fever or had exposure to typhoid fever within the last three years.
研究者
相似试验
已完成
3 期
A STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF BBIL?s TYPHOID Vi CAPSULAR POLYSACCHARIDE-TETANUS TOXOID PROTEIN CONJUGATE VACCINE VS REFERENCE VACCINE IN HEALTHY SUBJECTS.CTRI/2011/08/001957Bharat Biotech International Ltd981
进行中（未招募）
1 期
CLINICAL STUDY FINALIZED TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD TREATMENT WITH THE LENALIDOMIDE E DEXAMETHASONE DRUGS COMPARED WITH THE DOSE REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA THAT CAN NOT RECEIVE THE STANDARD CHEMIOTHERAPYELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004166-33-ITFO.NE.SA.Onlus200
招募中
不适用
A PHASE III, RANDOMISED, CONTROLLED, MULTI-CENTRE, 3-ARM STUDY OF NEOADJUVANT OSIMERTINIB AS MONOTHERAPY OR IN COMBINATION WITH CHEMOTHERAPY VERSUS STANDARD OF CARE CHEMOTHERAPY ALONE FOR THE TREATMENT OF PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION POSITIVE, RESECTABLE NON-SMALL CELL LUNG CANCER (NEOADAURA)-C349 Bronchus or lung, unspecifiedBronchus or lung, unspecifiedC349PER-091-20AstraZeneca AB,
已完成
不适用
A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDY TO DETERMINE THE EFFICACY OF ADJUVANT DURVALUMAB IN COMBINATIONWITH PLATINUM-BASED CHEMOTHERAPY IN COMPLETELY RESECTED STAGE II-IIINSCLC (MERMAID-1)PER-043-20AstraZeneca AB,
已完成
不适用
A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF DURVALUMAB FOR THE TREATMENT OF STAGE II-III NSCLC PATIENTS WITH MINIMAL RESIDUAL DISEASE FOLLOWING SURGERY AND CURATIVE INTENT THERAPY (MERMAID-2)-C349 Bronchus or lung, unspecifiedBronchus or lung, unspecifiedC349PER-077-20AstraZeneca AB,